(QURE) - Earnings & Price History

QURE: - 14.61, $387.75M, -0.29 (-1.95%)

Sector: Healthcare - Industry: Biotechnology

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company offers Glybera, a gene therapy product for the treatment of patients with lipoprotein lipase deficiency. It is also developing AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-110, a gene therapy that has been completed Phase I/II clinical trial for the treatment of sanfilippo B syndrome; AAV2/glial cell line-derived neurotrophic factor, which is in Phase I clinical trial for the treatment of parkinson's disease; S100A1, a preclinical product candidate for the treatment of congestive heart failure; AMT-130 for the treatment of huntington's disease; and AAV5 for the treatment of hemophilia A. The company has collaborations with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Tre

Past QURE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-15-0.596.286.336.016.016.35-5.06%4.49%-0.79%49.74K
2016-11-22-0.856.696.676.546.416.7-1.95%▲2.29%0.30%208.96K
2016-08-25-0.898.498.228.067.928.6-1.95%5.33%3.28%371.82K
2016-05-31-0.7313.4113.5513.781313.791.70%-2.69%-1.03%355.57K
2016-04-04-0.614.5713.313.0612.714.66-1.80%11.56%9.55%379.33K
2015-11-3019.818.7819.9319.33206.12%▲-0.65%5.43%632.76K
2015-11-2320.2719.2619.3419.0920.440.42%▲4.81%5.24%378.37K
2015-08-270.4925.7725.232524.3526.19-0.91%3.08%2.14%261.34K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades